CLINICAL_TRIALS
trial_result
· 2012-08-14
Clinical Trial Update: Peptide Vaccination for Patients at High Risk for Recurrent Melanoma [Phase 2]
Summary
A Phase 2 trial evaluated a peptide vaccine for patients at high risk of recurrent melanoma. The study is completed with results posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2012-08-14